Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) EPS (Weighted Average and Diluted) (2021 - 2025)

Protagonist Therapeutics' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.7 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 134.83% year-over-year to -$0.7; the TTM value through Dec 2025 reached -$2.05, down 148.46%, while the annual FY2025 figure was -$2.05, 148.46% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.7 at Protagonist Therapeutics, down from -$0.61 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $3.26 in Q1 2024 and bottomed at -$0.84 in Q2 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.6 (2023), against an average of -$0.23.
  • The largest annual shift saw EPS (Weighted Average and Diluted) skyrocketed 586.57% in 2024 before it plummeted 134.83% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.78 in 2021, then rose by 11.54% to -$0.69 in 2022, then soared by 178.26% to $0.54 in 2023, then surged by 272.22% to $2.01 in 2024, then plummeted by 134.83% to -$0.7 in 2025.
  • Per Business Quant, the three most recent readings for PTGX's EPS (Weighted Average and Diluted) are -$0.7 (Q4 2025), -$0.61 (Q3 2025), and -$0.55 (Q2 2025).